Theravance was founded in 1996 and is headquartered in South San Francisco, California. Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines across various therapeutic areas, including respiratory disease, bacterial infections, and gastrointestinal motility dysfunction. It offers Telavancin (cSSSI), a bactericidal injectable antibiotic for the treatment of complicated skin and skin structure infections; Telavancin (HAP) that is used to treat hospital-acquired pneumonia or nosocomial pneumonia; and Horizon to develop and commercialize long-acting beta2 agonist (LABA) product candidate as a single agent new medicine for the treatment of chronic obstructive pulmonary disease (COPD) and as part of a new combination medicine with an inhaled corticosteroid (ICS) for the treatment of asthma and/or a long acting muscarinic antagonist (LAMA) for COPD. In addition, it offers GSK961081, a bifunctional muscarinic antagonist-beta2 agonist compound, which is in phase 2 clinical studies; and TD-5108, a gastrointestinal motility dysfunction program for the treatment of chronic constipation and other disorders related to reduced gastrointestinal motility. The company has collaboration arrangements with Astellas Pharma, Inc. for the development and commercialization of Telavancin; GlaxoSmithKline plc to develop and commercialize LABA product candidates; and AstraZeneca AB to develop and commercialize intravenous anesthetic compounds. The company also has a strategic alliance with GlaxoSmithKline plc. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002.